Back to Search Start Over

Real-world clinical outcomes of treatment with casirivimab-imdevimab among patients with mild-to-moderate coronavirus disease 2019 during the Delta variant pandemic

Authors :
Yasuhito Suzuki
Yoko Shibata
Hiroyuki Minemura
Takefumi Nikaido
Yoshinori Tanino
Atsuro Fukuhara
Ryuzo Kanno
Hiroyuki Saito
Shuzo Suzuki
Taeko Ishii
Yayoi Inokoshi
Eiichiro Sando
Hirofumi Sakuma
Tatsuho Kobayashi
Hiroaki Kume
Masahiro Kamimoto
Hideko Aoki
Akira Takama
Takamichi Kamiyama
Masaru Nakayama
Kiyoshi Saito
Koichi Tanigawa
Masahiko Sato
Toshiyuki Kanbe
Norio Kanzaki
Teruhisa Azuma
Keiji Sakamoto
Yuichi Nakamura
Hiroshi Otani
Mitsuru Waragai
Shinsaku Maeda
Tokiya Ishida
Keishi Sugino
Yasuhiko Tsukada
Ryuki Yamada
Riko Sato
Takumi Omuna
Hikaru Tomita
Mikako Saito
Natsumi Watanabe
Mami Rikimaru
Takaya Kawamata
Takashi Umeda
Julia Morimoto
Ryuichi Togawa
Yuki Sato
Junpei Saito
Kenya Kanazawa
Ken Iseki
Source :
International Journal of Medical Sciences. 19:834-841
Publication Year :
2022
Publisher :
Ivyspring International Publisher, 2022.

Abstract

BackgroundMutations of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may reduce the efficacy of neutralizing monoclonal antibody therapy against coronavirus disease 2019 (COVID-19). We here evaluated the efficacy of casirivimab-imdevimab in patients with mild-to-moderate COVID-19 during the Delta variant surge in Fukushima Prefecture, Japan.MethodsWe enrolled 949 patients with mild-to-moderate COVID-19 who were admitted to hospital between July 24, 2021 and September 30, 2021. Clinical deterioration after admission was compared between casirivimab-imdevimab users (n = 314) and non-users (n = 635).ResultsThe casirivimab-imdevimab users were older (P < 0.0001), had higher body temperature (≥ 38°C) (P < 0.0001) and greater rates of history of cigarette smoking (P = 0.0068), hypertension (P = 0.0004), obesity (P < 0.0001), and dyslipidemia (P < 0.0001) than the non-users. Multivariate logistic regression analysis demonstrated that receiving casirivimab-imdevimab was an independent factor for preventing deterioration (odds ratio 0.448; 95% confidence interval 0.263–0.763; P = 0.0023). Furthermore, in 222 patients who were selected from each group after matching on the propensity score, deterioration was significantly lower among those receiving casirivimab-imdevimab compared to those not receiving casirivimab-imdevimab (7.66% vs 14.0%; p = 0.021).ConclusionThis real-world study demonstrates that casirivimab-imdevimab contributes to the prevention of deterioration in COVID-19 patients after hospitalization during a Delta variant surge.SummaryThis real-world retrospective study demonstrates the contribution of treatment with casirivimab-imdevimab to the prevention of deterioration in patients with mild-to-moderate coronavirus disease 2019 (COVID-19) even during the Delta variant pandemic.

Details

ISSN :
14491907
Volume :
19
Database :
OpenAIRE
Journal :
International Journal of Medical Sciences
Accession number :
edsair.doi.dedup.....22e2958abeb4fdc384af49979d26800a
Full Text :
https://doi.org/10.7150/ijms.71132